Attached files

file filename
Washington, D.C. 20549

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: March 2, 2017
(Date of earliest event reported)
ImmuCell Corporation
(Exact name of registrant as specified in its charter)
DE 001-12934 01-0382980
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)
56 Evergreen Drive, Portland, Maine 04103
(Address of principal executive offices) (Zip Code)
(Registrant's telephone number, including area code)
Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01. Entry into a Material Definitive Agreement

Item 8.01. Other Events
During the first quarter of 2016, the Company entered into bank debt agreements covering certain additional credit facilities with TD Bank N.A. aggregating approximately $4.5 million. As a result of loan amendments entered into with TD Bank N.A. on March 1, 2017, these credit facilities now aggregate up to $6.5 million. These credit facilities are secured by substantially all Company assets and are subject to certain financial covenants. There are presently no amounts outstanding under these facilities.

The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 2, 2017 ImmuCell Corporation

By: /s/ Michael F. Brigham
     Michael F. Brigham
     President, Chief Executive Officer and Principal Financial Officer

Exhibit Index